Top Stories
The partnership will bring Cradle’s AI models into UCB’s existing research programmes, with lab results helping scientists decide which antibody designs to test next.
Ramantamig, which targets BCMA and GPRC5D, generated complete responses or better in 81% of newly diagnosed, transplant-eligible patients.
Ultragenyx wants to bring its R&D expenses below $350 million next year.
ASKA has agreed to pay $110M upfront for certain rights to the Phase III antibody MHB018A, which could eventually compete with drugs from Amgen and Viridian.
The separation is expected to be completed in the first half of 2028.
Conference News
– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refr...
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment SensitivityFindings Suggest Low TROP2 Expression is Associ...
Studies highlight persistent challenges in lupus diagnosis and access to specialty care, while advancing more inclusive approaches to research and treatmentORLANDO, Fla., Nov. 4, 2026 /PRNewswire/ -- ...
HOUSTON, Nov. 4, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-e...
